Ashton Thomas Securities LLC Purchases Shares of 6,843 Pfizer Inc. (NYSE:PFE)

Ashton Thomas Securities LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,843 shares of the biopharmaceutical company’s stock, valued at approximately $198,000.

Several other hedge funds and other institutional investors have also made changes to their positions in PFE. Olistico Wealth LLC purchased a new position in Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. acquired a new position in Pfizer during the second quarter worth $34,000. Finally, ESL Trust Services LLC acquired a new position in Pfizer during the first quarter worth $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 1.8 %

Shares of PFE opened at $26.24 on Tuesday. The company has a market capitalization of $148.70 billion, a P/E ratio of 35.46, a PEG ratio of 0.85 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The business’s 50 day simple moving average is $28.89 and its 200-day simple moving average is $28.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the business earned ($0.17) EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.40%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.